A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma

Research output: Contribution to journalLetter

Authors

  • Guy Pratt
  • Rebecca Bishop
  • Mike Griffiths
  • Martin J S Dyer
  • Chris Fegan
  • David Oscier
  • Andrew Pettitt
  • Estella Matutes
  • Stephen Devereux
  • David Allsup
  • Adrian Bloor
  • Peter Hillmen
  • George Follows
  • Simon Rule

External organisations

  • University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
  • West Midlands Regional Genetics Laboratory, Birmingham, UK
  • University of Leicester
  • Cardiff and Vale University Health board, University Hospital of Wales, Cardiff, UK.
  • Royal Bournemouth Hospital, The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Bournemouth, UK.
  • The Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK.
  • Department of Medicine, Royal Marsden NHS Foundation Trust, London
  • Institute of Liver Studies, King's College Hospital NHS Foundation Trust, London, UK.
  • Hull York Medical School, East Yorkshire
  • St James University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
  • Addenbrookes Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Cardiothoracic Department; Plymouth Hospitals NHS Trust; Plymouth UK
  • The Christie NHS Foundation Trust
  • University of Manchester

Details

Original languageEnglish
Pages (from-to)429-433
JournalBritish Journal of Haematology
Volume182
Issue number3
Early online date23 Jun 2017
Publication statusPublished - Aug 2018

Keywords

  • Letter, chronic lymphocytic leukaemia, mantle cell lymphoma, DNA damage, olaparib